^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Oncomine™ Pan-Cancer Cell-Free Assay

    Company:
    Thermo Fisher Scientific
    Type:
    Laboratory Developed Test
    Related tests:
    Evidence Level:
    Sensitive: C3 – Early Trials

    [BRAF G464-Non Small Cell Lung Cancer-Immunotherapy]

    Source:
    IASLC-WCLC 2023
    Test:

    Oncomine™ Pan-Cancer Cell-Free Assay

    Title:
    BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy
    Published date:
    08/08/2023
    Excerpt:
    In NADIM trials, pathogenic or likely pathogenic genetic alterations in the BRAF gene occurred in 4.35% of the patients (n=4; p.L597Q, p.G469V, p.G464, p.V600E). BRAF pathogenic mutations were significantly enriched in tumors showing pathological complete response after neoadjuvant treatment with chemo-immunotherapy.
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: C3 – Early Trials

    [BRAF V600E-Non Small Cell Lung Cancer-Immunotherapy]

    Source:
    IASLC-WCLC 2023
    Test:

    Oncomine™ Pan-Cancer Cell-Free Assay

    Title:
    BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy
    Published date:
    08/08/2023
    Excerpt:
    In NADIM trials, pathogenic or likely pathogenic genetic alterations in the BRAF gene occurred in 4.35% of the patients (n=4; p.L597Q, p.G469V, p.G464, p.V600E). BRAF pathogenic mutations were significantly enriched in tumors showing pathological complete response after neoadjuvant treatment with chemo-immunotherapy.
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: C3 – Early Trials

    [BRAF L597Q-Non Small Cell Lung Cancer-Immunotherapy]

    Source:
    IASLC-WCLC 2023
    Test:

    Oncomine™ Pan-Cancer Cell-Free Assay

    Title:
    BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy
    Published date:
    08/08/2023
    Excerpt:
    In NADIM trials, pathogenic or likely pathogenic genetic alterations in the BRAF gene occurred in 4.35% of the patients (n=4; p.L597Q, p.G469V, p.G464, p.V600E). BRAF pathogenic mutations were significantly enriched in tumors showing pathological complete response after neoadjuvant treatment with chemo-immunotherapy.
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: C3 – Early Trials

    [BRAF G469V-Non Small Cell Lung Cancer-Immunotherapy]

    Source:
    IASLC-WCLC 2023
    Test:

    Oncomine™ Pan-Cancer Cell-Free Assay

    Title:
    BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy
    Published date:
    08/08/2023
    Excerpt:
    In NADIM trials, pathogenic or likely pathogenic genetic alterations in the BRAF gene occurred in 4.35% of the patients (n=4; p.L597Q, p.G469V, p.G464, p.V600E). BRAF pathogenic mutations were significantly enriched in tumors showing pathological complete response after neoadjuvant treatment with chemo-immunotherapy.
    Secondary therapy:
    Chemotherapy